{
  "success": true,
  "sourceFile": "C:\\Users\\panik\\Documents\\GitHub\\Protcol2USDMv3\\input\\trial\\NCT02163694_BROCADE3\\NCT02163694_BROCADE3_SAP.pdf",
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36
  ],
  "modelUsed": "gemini-3-flash-preview",
  "sapData": {
    "analysisPopulations": [
      {
        "id": "pop_1",
        "name": "ITT population",
        "text": "Includes randomized subjects who have been documented to have suspected deleterious or deleterious mutations by the sponsor core lab. In this population subjects will be grouped according to the treatment assigned at randomization.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "ITT",
        "populationDescription": "Includes randomized subjects who have been documented to have suspected deleterious or deleterious mutations by the sponsor core lab. In this population subjects will be grouped according to the treatment assigned at randomization.",
        "criteria": "Randomized AND documented suspected deleterious or deleterious BRCA mutations by sponsor core lab"
      },
      {
        "id": "pop_2",
        "name": "As-Treated population",
        "text": "Includes subjects who receive at least one dose of study drug (veliparib or placebo). In this population subjects will be grouped by the actual treatment received on the first dosing day.",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "label": "AST",
        "populationDescription": "Includes subjects who receive at least one dose of study drug (veliparib or placebo). In this population subjects will be grouped by the actual treatment received on the first dosing day.",
        "criteria": "Received at least one dose of study drug (veliparib or placebo)"
      },
      {
        "id": "pop_3",
        "name": "Crossover population",
        "text": "Includes subjects who receive at least one dose of veliparib in the crossover study period.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "Crossover",
        "populationDescription": "Includes subjects who receive at least one dose of veliparib in the crossover study period.",
        "criteria": "Received at least one dose of veliparib during the crossover study period"
      }
    ],
    "characteristics": [
      {
        "id": "char_1",
        "name": "Age",
        "code": "AGE",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Age",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Age at baseline"
      },
      {
        "id": "char_2",
        "name": "BRCA Status",
        "code": "BRCA_STATUS",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "BRCA Status",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Core lab and historical BRCA1 and BRCA2 status"
      },
      {
        "id": "char_3",
        "name": "ER/PgR status",
        "code": "ER/PGR_STATUS",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "ER/PgR status",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Estrogen receptor and/or progesterone receptor status (ER/PgR+, triple-negative)"
      },
      {
        "id": "char_4",
        "name": "CNS Metastases",
        "code": "CNS_METASTASES",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "CNS Metastases",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Presence or absence of central nervous system metastases"
      },
      {
        "id": "char_5",
        "name": "Prior Platinum Therapy",
        "code": "PRIOR_PLATINUM_THERA",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Prior Platinum Therapy",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "History of prior platinum therapy use (yes versus no)"
      },
      {
        "id": "char_6",
        "name": "ECOG Performance Status",
        "code": "ECOG_PERFORMANCE_STA",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "ECOG Performance Status",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Eastern Cooperative Oncology Group performance status at baseline"
      }
    ],
    "summary": {
      "populationCount": 3,
      "characteristicCount": 6
    }
  }
}